The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Autolus Therapeutics Limited Common 05280R100 238 39,740 SH   SOLE   39,740 0 0
CytomX Therapeutics, Inc. Common 23284F105 6,561 855,437 SH   SOLE   855,437 0 0
Epizyme, Inc. Common 29428V104 36,162 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 15,690 1,423,794 SH   SOLE   1,423,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 45,144 3,898,422 SH   SOLE   3,898,422 0 0
MEI Pharma, Inc. Common 552798202 10,063 6,250,000 SH   SOLE   6,250,000 0 0
Sunesis Pharmaceuticals, Inc. Common 867328700 1,166 2,809,912 SH   SOLE   2,809,912 0 0
TCR2 Therapeutics, Inc. Common 87808K106 26,091 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 13,786 308,686 SH   SOLE   308,686 0 0
YmAbs Therapeutics, Inc. Common 984241109 8,803 337,291 SH   SOLE   337,291 0 0